JP2004532038A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532038A5
JP2004532038A5 JP2002589648A JP2002589648A JP2004532038A5 JP 2004532038 A5 JP2004532038 A5 JP 2004532038A5 JP 2002589648 A JP2002589648 A JP 2002589648A JP 2002589648 A JP2002589648 A JP 2002589648A JP 2004532038 A5 JP2004532038 A5 JP 2004532038A5
Authority
JP
Japan
Prior art keywords
antigen binding
amino acid
mutated
nucleic acid
encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002589648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/015767 external-priority patent/WO2002092780A2/en
Publication of JP2004532038A publication Critical patent/JP2004532038A/ja
Publication of JP2004532038A5 publication Critical patent/JP2004532038A5/ja
Pending legal-status Critical Current

Links

JP2002589648A 2001-05-17 2002-05-17 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法 Pending JP2004532038A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30038101P 2001-05-17 2001-05-17
US30090701P 2001-06-25 2001-06-25
PCT/US2002/015767 WO2002092780A2 (en) 2001-05-17 2002-05-17 Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

Publications (2)

Publication Number Publication Date
JP2004532038A JP2004532038A (ja) 2004-10-21
JP2004532038A5 true JP2004532038A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=26971759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002589648A Pending JP2004532038A (ja) 2001-05-17 2002-05-17 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法

Country Status (3)

Country Link
EP (1) EP1421203A4 (cg-RX-API-DMAC7.html)
JP (1) JP2004532038A (cg-RX-API-DMAC7.html)
WO (1) WO2002092780A2 (cg-RX-API-DMAC7.html)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
AU2004299833B2 (en) 2003-12-10 2009-05-07 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses
KR101333449B1 (ko) 2003-12-10 2013-11-26 메다렉스, 엘.엘.시. Ip―10 항체 및 그의 용도
RU2412202C2 (ru) 2004-06-21 2011-02-20 Медарекс, Инк. Антитела рецептора 1 интерферона альфа и их применение
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
MX2007015944A (es) 2005-06-20 2008-03-07 Medarex Inc Anticuerpos cd19 y sus usos.
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
KR101461263B1 (ko) 2005-10-21 2014-11-17 노파르티스 아게 Il-13에 대항한 인간 항체 및 치료적 용도
CA2638902C (en) 2005-12-08 2014-09-23 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
MX2009001341A (es) 2006-08-04 2009-05-28 Novartis Ag Anticuerpos especificos de ephb3 y usos de los mismos.
JP5244785B2 (ja) 2006-08-11 2013-07-24 小野薬品工業株式会社 ストローマ由来因子−1(sdf−1)に対するモノクローナル抗体
HRP20140081T1 (hr) 2006-08-18 2014-03-28 Novartis Ag Prlr-specifiäśna antitijela i njihova uporaba
CN101627055A (zh) 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
RS55740B1 (sr) 2006-10-02 2017-07-31 Squibb & Sons Inc Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
AU2007319605B2 (en) 2006-10-19 2011-02-17 Csl Limited Anti-IL-13R alpha 1 antibodies and their uses thereof
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
NZ577085A (en) 2006-11-15 2012-06-29 Medarex Inc Human monoclonal antibodies to btla and methods of use
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
LT2769729T (lt) 2007-09-04 2019-05-10 Compugen Ltd. Polipeptidai ir polinukleotidai ir jų panaudojimas kaip vaistų taikinio vaistų ir biologinių preparatų gamybai
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素(sclerostin)抗體組合物及使用方法
EP2567709B1 (en) 2007-11-02 2017-12-27 Novartis AG Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
CA2708854C (en) 2007-12-14 2017-11-28 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
RU2528736C2 (ru) 2008-02-05 2014-09-20 Бристоль-Мейерз Сквибб Компани Антитела против альфа5-бета 1 и их применение
JP5504587B2 (ja) * 2008-05-27 2014-05-28 東レ株式会社 分析用チップ
HUE026179T2 (en) 2008-08-05 2016-05-30 Novartis Ag Preparations and methods for antibodies against complement C5 protein
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
PL2403878T3 (pl) 2009-03-05 2017-12-29 E. R. Squibb & Sons, L.L.C. W pełni ludzkie przeciwciała specyficzne dla CADM1
EP2421898B1 (en) 2009-04-20 2016-03-16 Oxford BioTherapeutics Ltd Antibodies specific to cadherin-17
DK2424895T3 (en) 2009-04-27 2017-12-18 Novartis Ag Compositions and Methods for Increasing Muscle Growth
US8715657B2 (en) 2009-04-27 2014-05-06 Novartis Ag Therapeutic antibodies binding IL12Rβ1
DK3042957T3 (en) * 2009-07-17 2018-01-02 Bioatla Llc At the same time, integrated selection and development of human protein performance and expression in production hosts
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
EP2552947A4 (en) 2010-03-26 2013-11-13 Dartmouth College VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING ACTIVE SUBSTANCES AND USE THEREOF
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CN103237811A (zh) 2010-05-06 2013-08-07 诺瓦提斯公司 用于治疗性低密度脂蛋白相关蛋白质6(lrp6)多价抗体的组合物及使用方法
ES2659406T3 (es) 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
SG187033A1 (en) 2010-07-16 2013-02-28 Bioatla Llc Novel methods of protein evolution
EP2603224A1 (en) 2010-08-09 2013-06-19 Cyvax, Inc. Methods and compositions for preventing a condition
PH12013500333A1 (en) 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
EP2616100B1 (en) 2010-09-17 2016-08-31 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
CA3182320A1 (en) 2010-09-23 2012-03-29 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
EP2625203A1 (en) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
EP2658971A1 (en) 2010-12-28 2013-11-06 XOMA Technology Ltd. Cell surface display using pdz domains
SG194099A1 (en) 2011-04-15 2013-11-29 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
BR112013030958B1 (pt) 2011-06-03 2022-02-08 Xoma Technology Ltd Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
BR112013032621A2 (pt) 2011-06-28 2017-01-24 Oxford Biotherapeutics Ltd anticorpos
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
DK2726099T3 (en) 2011-07-01 2018-11-05 Novartis Ag Method of treating metabolic disorders
JP2015500829A (ja) 2011-12-05 2015-01-08 ノバルティス アーゲー 上皮細胞増殖因子受容体3(her3)のドメインiiに対するher3の抗体
ES2758433T3 (es) 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
CA2859493A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
EP2756093A4 (en) 2012-02-01 2015-07-01 Compugen Ltd C10RF32 ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
DK3421486T5 (da) 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
CN104968678B (zh) 2012-12-05 2018-12-11 诺华股份有限公司 靶向epo的抗体的组合物和方法
MX2015007931A (es) 2012-12-18 2015-10-05 Novartis Ag Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
NZ709828A (en) 2012-12-28 2019-07-26 Prec Biologics Inc Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
SG11201505330QA (en) 2013-02-08 2015-08-28 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
EP3611189A1 (en) 2013-03-14 2020-02-19 Novartis AG Antibodies against notch 3
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
CN105960414A (zh) 2013-08-14 2016-09-21 诺华股份有限公司 治疗散发性包涵体肌炎的方法
IL301714A (en) 2013-12-24 2023-05-01 Janssen Pharmaceutica Nv Antibodies and anti-VISTA fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
MX389695B (es) 2014-06-11 2025-03-20 Kathy A Green Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
AP2017009721A0 (en) 2014-08-07 2017-01-31 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
CA2969730A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
RS63897B1 (sr) 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena
WO2016193872A2 (en) 2015-06-05 2016-12-08 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
CN114805576A (zh) 2015-06-24 2022-07-29 詹森药业有限公司 抗vista抗体和片段
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3331914A1 (en) 2015-08-03 2018-06-13 Novartis AG Methods of treating fgf21-associated disorders
KR20180042433A (ko) 2015-09-09 2018-04-25 노파르티스 아게 흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
UY36889A (es) 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
JP2019506844A (ja) 2015-12-18 2019-03-14 ノバルティス アーゲー CD32bを標的とする抗体およびその使用方法
BR112018016461A2 (pt) 2016-02-12 2019-10-01 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
CA3020848A1 (en) 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anti-human vista antibodies and use thereof
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子15に対する抗体およびそれらの使用
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CA3027651A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
EP4512829A3 (en) 2016-07-14 2025-06-11 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018027042A1 (en) 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
AU2017383232B2 (en) 2016-12-23 2024-09-12 Novartis Ag Factor XI antibodies and methods of use
US11111277B2 (en) 2016-12-28 2021-09-07 Invvax, Inc. Influenza vaccines
KR102572663B1 (ko) 2017-02-08 2023-09-01 노파르티스 아게 Fgf21 모방 항체 및 이의 용도
KR20240014600A (ko) 2017-03-24 2024-02-01 노바르티스 아게 심장질환 예방 및 치료 방법
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
AU2018291082B2 (en) 2017-06-27 2025-05-29 Neuracle Science Co., Ltd. Anti-FAM19A5 antibodies and uses thereof
WO2019003104A1 (en) 2017-06-28 2019-01-03 Novartis Ag METHOD FOR PREVENTING AND TREATING URINARY INCONTINENCE
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
AU2018372135A1 (en) 2017-11-22 2020-05-28 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
US11970532B2 (en) 2018-05-10 2024-04-30 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
EP3898700A1 (en) 2018-12-18 2021-10-27 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2020136218A1 (en) 2018-12-26 2020-07-02 Imcheck Therapeutics Sas Btn3a binding proteins and uses thereof
CA3117619A1 (en) 2019-01-02 2020-07-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
CN113396162B (zh) 2019-01-22 2024-08-16 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與entpd2抗體之組合療法
MX2023000547A (es) 2020-07-16 2023-02-13 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
US12018254B2 (en) * 2020-07-27 2024-06-25 Wisconsin Alumni Research Foundation Methods of making unbiased phage libraries
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
JP2025516472A (ja) 2022-05-10 2025-05-30 イムチェック セラピューティクス エスエーエス 胃腸炎症性障害を処置する方法における使用のための抗btn3a抗体
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4251406B2 (ja) * 1990-04-05 2009-04-08 クレア,ロベルト ウォーク―スルー突然変異誘発
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6238884B1 (en) * 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
KR20010085850A (ko) * 1998-09-29 2001-09-07 추후제출 코돈 변형 유전자의 재편성
JP2002537836A (ja) * 1999-03-09 2002-11-12 ディベルサ コーポレーション 定方向進化におけるエンドセレクション

Similar Documents

Publication Publication Date Title
JP2004532038A5 (cg-RX-API-DMAC7.html)
JP2005514030A5 (cg-RX-API-DMAC7.html)
Hanes et al. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display
US6010861A (en) Target specific screens and their use for discovering small organic molecular pharmacophores
JP2019195335A5 (cg-RX-API-DMAC7.html)
JP4829457B2 (ja) 抗体模倣物および他の結合タンパク質のタンパク質骨格
AU2002211099B2 (en) Identification of protein binding sites
WO2002092780A3 (en) Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
CN114303201A (zh) 使用机器学习技术生成蛋白质序列
Smith et al. Changing the peptide specificity of a human T-cell receptor by directed evolution
CA2291721A1 (en) Ribosome complexes as selection particles for in vitro display and evolution of proteins
JP2012533307A5 (cg-RX-API-DMAC7.html)
JP2013509878A5 (cg-RX-API-DMAC7.html)
JP2007501011A5 (cg-RX-API-DMAC7.html)
JP2010534828A5 (cg-RX-API-DMAC7.html)
CN112969708B (zh) 缺乏免疫球蛋白fc结构域结合亲和力的新三螺旋多肽及其用途
CN114008713A (zh) 信息处理系统、信息处理方法、程序、以及制备抗原结合分子或蛋白质的方法
CN104530228B (zh) 一种人源抗乙肝病毒表面抗体及其制备方法和应用
TW202128766A (zh) 提升抗體對抗原之親和性的方法及其用途
JP2002544237A5 (cg-RX-API-DMAC7.html)
EP3650465A1 (en) Novel populations of polypeptides having a triple-helical structure
Konthur et al. High-throughput applications of phage display in proteomic analyses
JP2004509858A5 (cg-RX-API-DMAC7.html)
WO2000021985A3 (en) Genes encoding olfactory receptors and biallelic markers thereof
He et al. Arraying proteins by cell-free synthesis